title: Low incidence of adverse events following 90-minute and 3-minute infusions of intravenous iron sucrose in children on erythropoietin.
abstract: OBJECTIVE
  To define the adverse events following two different rates and methods of intravenous iron sucrose infusions in children with anaemia due to chronic renal impairment.
  
  
  METHODS
  Two prospective observational studies were undertaken to characterize the adverse events following iron sucrose administration in children with renal impairment and on erythropoietin. Between January 1999 and April 2003, 5 mg/kg of intravenous (IV) iron sucrose was given over 90 min and repeated 24 h later. Between May 2003 and September 2004, in children with better venous access, a single dose of 2 mg/kg of IV iron sucrose was administered over 3 min during an outpatient clinic visit and haemodialysis sessions. Following infusions, children were monitored for immediate and delayed adverse events. All such events were documented and dealt with appropriately. Test doses were not used.
  
  
  RESULTS
  A total of 870 infusions over 90 min were administered to 72 children. Three children developed abdominal pain. One child developed worsening of hypertension (not related to iron sucrose). Sixty-five doses were administered over 3 min to 20 children, and six minor adverse events were documented.
  
  
  CONCLUSIONS
  Although 90 min infusion is associated with fewer adverse events, no life-threatening events were documented in either method.
authors.affiliation: Department of Paediatric Nephrology, Royal Manchester Children's Hospital, Manchester, United Kingdom.
authors.forename: Anbarasu Theodore
authors.initials: AT
authors.lastname: Anbu
authors.forename: Timothy
authors.initials: T
authors.lastname: Kemp
authors.forename: Kate
authors.initials: K
authors.lastname: O'donnell
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Smith
authors.forename: Mark G
authors.initials: MG
authors.lastname: Bradbury
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D002648:Child; D004921:Erythropoietin / Q000627:therapeutic use*; D005290:Ferric Compounds / Q000008:administration & dosage* / Q000009:adverse effects*; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid; D006801:Humans; D007262:Infusions, Intravenous; D007676:Kidney Failure, Chronic / Q000150:complications; D011446:Prospective Studies; D011994:Recombinant Proteins
chemical_list: D005290:Ferric Compounds; D011994:Recombinant Proteins; D004921:Erythropoietin; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid